Karyopharm Therapeutics/$KPTI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
Ticker
$KPTI
Sector
Primary listing
Employees
228
Headquarters
Website
KPTI Metrics
BasicAdvanced
$122M
-
-$17.93
0.20
-
Price and volume
Market cap
$122M
Beta
0.2
52-week high
$10.99
52-week low
$3.51
Average daily volume
802K
Financial strength
Current ratio
1.12
Quick ratio
0.977
Long term debt to equity
-96.941
Total debt to equity
-102.153
Interest coverage (TTM)
-1.98%
Profitability
EBITDA (TTM)
-90.411
Gross margin (TTM)
9.93%
Net profit margin (TTM)
-134.21%
Operating margin (TTM)
-62.10%
Effective tax rate (TTM)
-0.02%
Revenue per employee (TTM)
$640,000
Management effectiveness
Return on assets (TTM)
-41.56%
Return on equity (TTM)
81.86%
Valuation
Price to revenue (TTM)
0.499
Price to book
-0.42
Price to tangible book (TTM)
-0.42
Price to free cash flow (TTM)
-0.966
Free cash flow yield (TTM)
-103.49%
Free cash flow per share (TTM)
-6.892
Growth
Revenue change (TTM)
0.57%
Earnings per share change (TTM)
28.04%
3-year revenue growth (CAGR)
-2.39%
10-year revenue growth (CAGR)
89.09%
3-year earnings per share growth (CAGR)
-16.05%
10-year earnings per share growth (CAGR)
-9.71%
KPTI News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Karyopharm Therapeutics stock?
Karyopharm Therapeutics (KPTI) has a market cap of $122M as of March 24, 2026.
What is the P/E ratio for Karyopharm Therapeutics stock?
The price to earnings (P/E) ratio for Karyopharm Therapeutics (KPTI) stock is 0 as of March 24, 2026.
Does Karyopharm Therapeutics stock pay dividends?
No, Karyopharm Therapeutics (KPTI) stock does not pay dividends to its shareholders as of March 24, 2026.
When is the next Karyopharm Therapeutics dividend payment date?
Karyopharm Therapeutics (KPTI) stock does not pay dividends to its shareholders.
What is the beta indicator for Karyopharm Therapeutics?
Karyopharm Therapeutics (KPTI) has a beta rating of 0.2. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.